



## The Era of Personalized Medicine in the Landscape of Rare Tumors

Guest Editors:

**Dr. Toni Ibrahim**

**Dr. Laura Mercatali**

**Dr. Alessandro De Vita**

**Dr. Chiara Liverani**

Deadline for manuscript  
submissions:

**closed (31 May 2023)**

### Message from the Guest Editors

The interest in personalized medicine, also referred to as precision medicine, has been rapidly growing in the last decade. This is especially evident in the field of rare tumors, which represent a heterogeneous group of solid malignancies accounting for 20–25% of all neoplasms. Today, about 250 different entities are recognized by the WHO. Their extraordinary diversity in terms of diagnosis, prognosis, and therapy affects patient management, which is still challenging compared to that of common tumor types. In order to solve the unmet scientific and clinical needs, personalized medicine has been proposed as a new window of opportunity.

This Special Issue will cover all aspects around recent advancements in the field of personalized medicine in the panorama of rare tumors. Original articles, reviews, and case reports are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)